1 Warfarin should
be continued for 1 month after cardioversion to allow fo
2 Therapy has
been continued for 1 year in responders.
3 In 15 patients, the drug
was continued for 1 to 14 days while other possible caus
4 Durvalumab
was continued for 1 year after surgery.
5 r 12 weeks with trastuzumab, and trastuzumab
was continued for 1 year.
6 Treatment with study drug
was continued for 10 days, until the peak white blood ce
7 cin after becoming bacteremic, and treatment
was continued for 10 days.
8 Chest compressions and ventilation
were continued for 10 mins.
9 ng macrolide, rifamycin, and ethambutol that
is continued for 12 months beyond sputum culture convers
10 in lesion area gradually subsided as the WTD
was continued for 12 and 16 weeks.
11 one of the four irbesartan doses, treatment
was continued for 12 weeks and hemodynamic measurements
12 by gavage starting at 16 weeks after VC and
was continued for 12 weeks.
13 09, 3 mg/kg/d) was given 1 week after MI and
was continued for 12 weeks.
14 was seen in those patients in whom anakinra
was continued for 12 weeks.
15 This chemotherapy
was continued for 13 total courses for some patients, wh
16 itiated 11 days after MAb administration and
was continued for 13 weeks in all treated animals.
17 Pacing
was continued for 14 days, and final studies were obtain
18 oped but was reduced when allergen challenge
was continued for 15 days.
19 Drug treatment
was continued for 15 weeks.
20 Therapy
was continued for 176 +/- 117 days, and follow-up includ
21 Maintenance injections
were continued for 18 months or longer.
22 doscopic hemostasis, vasoactive drugs should
be continued for 2-5 days to prevent early rebleeding.
23 Normothermic perfusion
was continued for 2 hr before in situ cold perfusion wit
24 ot successful, cardiopulmonary resuscitation
was continued for 2 mins before the next defibrillation.
25 the drinking water, and the cholesterol diet
was continued for 2 weeks, at which time the aortas were
26 Study drug
was continued for 24 to 72 hours, and Holter monitoring
27 le after exposure (within 72 hours) and must
be continued for 28 days.
28 gents was started about 1 week after MNU and
was continued for 29 weeks with DFMO.
29 Subsequent ex vivo perfusion
was continued for 3 h at 15 degrees C, followed by 3 h w
30 Subsequent ex vivo perfusion at 15 degrees C
was continued for 3 h, followed by 3 h with red blood ce
31 In the remaining 9 dogs, reperfusion
was continued for 3 hours, when MCE was repeated before
32 gs (SHAM, n = 4; CHADN, n = 5) the HFHF diet
was continued for 3 months postsurgery and the improveme
33 ed after 1 week as penile rehabilitation and
was continued for 3 months.
34 tinued, but the diet with Gln or Gln placebo
was continued for 3 months.
35 Treatment
was continued for 3 months.
36 ed to active drug, and prospective follow-up
was continued for 3 years.
37 with oral methotrexate and 6-mercaptopurine
was continued for 30 months.
38 Cardiopulmonary resuscitation
was continued for 307 minutes after rescue until venoart
39 Treatment
was continued for 39 cycles, for 36 months, or until con
40 The inhaled prostacyclin
was continued for 4 days postoperatively, with no signs
41 quid ventilation or conventional ventilation
was continued for 4 hrs before the animals were killed.
42 The combination antimicrobial therapy
was continued for 42 days and the infection was successf
43 Selective brain cooling
was continued for 45 mins of reperfusion after which pas
44 The scan
was continued for 45 minutes after levodopa intake or un
45 centrations or Ringer solution and perfusion
was continued for 45-60 min.
46 activity; the St John's wort dosing regimen
was continued for 48 hours.
47 Treatment
was continued for 48 weeks if patients had undetectable
48 was started within 24 hrs of enrollment and
was continued for 5 days or until the white blood cell c
49 iven 24 hours after infection, and treatment
was continued for 5 days.
50 began showing signs of growth and treatment
was continued for 5 weeks.
51 Ventilation
was continued for 5.5 hrs.
52 All regimens
were continued for 5 days.
53 hemotherapy or biological therapy and should
be continued for 6-12 months after discontinuation of su
54 ects at higher dosages; (3) treatment should
be continued for 6-12 months to potentially prevent rela
55 Interferon-alpha therapy
was continued for 6 to 9 months in the eight patients ju
56 Both conditions
were continued for 6 weeks.
57 , when exposure of the differentiating cells
was continued for 6days, AC activities then became supra
58 copic plugged catheter, antibiotic treatment
was continued for 7 days.
59 Diets and linseed oil supplementation
were continued for 7 to 12 weeks.
60 red for 2 wk before inoculation of tumor and
was continued for 8 wk, resulting in significant inhibit
61 ingual and subcutaneous immunotherapy should
be continued for a minimum of 3 years to achieve disease
62 Treatment was to
be continued for a minimum of 6 months and a maximum of
63 loxifene will gain BMD if the same treatment
is continued for a second year.
64 administered for 1 week prior to lesion and
was continued for a further 2 weeks.
65 eye combinations were reversed and lens wear
was continued for a further 6 months, followed by anothe
66 However, when ethanol treatment
was continued for a longer time, there was a significant
67 Treatment
was continued for a maximum of 16 weeks.
68 Maintenance
was continued for a maximum of four rituximab courses or
69 Therapy
was continued for a maximum of six cycles.
70 of 2 weeks; step-down therapy with an azole
was continued for a median duration of 12 months.
71 Therapy
was continued for a minimum of 48 hours to a maximum of
72 23 BLTx for severe PH, ECMO used during BLTx
was continued for a minimum of 5 days (BLTx-ECMO group).
73 ablation of an enlarging metastasis, and ICI
was continued for a minimum of two additional cycles.
74 The intervention
was continued for a third year, permitting evaluation of
75 Treatment
was continued for a total of 230 mins.
76 Endocrine therapy
was continued for a total of 5 years, and breast irradia
77 Study interventions
were continued for a median (IQR) of 41 (30-57) days and
78 n, or high-frequency oscillatory ventilation
was continued for an additional 4 hrs before the animals
79 e of the latter experiment), the superfusion
was continued for another 115 min.
80 oved, and iloprost or normal saline infusion
was continued for another 60 mins.
81 he abdomen was manually deflated; monitoring
was continued for another 60 minutes.
82 After device implantation, warfarin
was continued for approximately 45 days, followed by clo
83 Treatment
was continued for as long as the patients derived clinic
84 The simulations
are continued for at least 1s of leukocyte rolling durin
85 tibiotics ordered in critically ill patients
are continued for at least 72 hours in absence of adjudi
86 eatment of GAD with an antidepressant should
be continued for at least 12 months.
87 of disease progression, and treatment should
be continued for at least 12 weeks to ensure adequate dr
88 s once an influenza outbreak is detected and
be continued for at least 14 days and until 7 days after
89 ecurrence of pericarditis, colchicine should
be continued for at least 6 months.
90 Treatment
was continued for at least 24 months in patients who sho
91 Of the empiric antibiotics, 333 of 660 (50%)
were continued for at least 72 hours in instances where
92 Ibrutinib monotherapy
was continued for cycles 13 through 36 in patients not r
93 seeking novel solid-state electrolytes have
been continued for decades.
94 ated if suppressive antiretroviral treatment
is continued for extremely long periods of time.
95 er completion of local therapy, chemotherapy
was continued for four to 15 cycles, followed by radioth
96 Medications
were continued for four weeks, at which time, the final
97 Trial medication
was continued for half a year or longer, for a maximum o
98 However, treatment has to
be continued for life because it does not lead to the fu
99 larger decrements in life expectancy if HRT
was continued for life (-0.79 to -1.09 years).
100 ide reverse transcriptase inhibitors (NRTIs)
were continued for median nine days after NNRTI interrup
101 agnosis of JIA is suspected or confirmed and
be continued for more than 8 years after the diagnosis o
102 cally treated patients, antibiotic treatment
was continued for more than 24 hours because of acute co
103 ension, the question of how long they should
be continued for prevention of variceal hemorrhage remai
104 b was administered at the end of cycle 1 and
was continued for seven cycles.
105 However, as the treatment usually needs to
be continued for several years to be effective, and can
106 The drug therapy
was continued for six months post-operatively.
107 , social distancing, and mask-wearing should
be continued for the foreseeable future.
108 eatment began on the same day as surgery and
was continued for the 16-day duration of study.
109 e infusion with iloprost or carrier solution
was continued for the duration of the experiment.
110 as prevented when weekly doses of tacrolimus
were continued for the duration of the experiment rather
111 tions, including SGLT-2 inhibitor treatment,
were continued for the duration of the trial.
112 After 8 weeks, dexamethasone mouthwash could
be continued for up to eight additional weeks at the dis
113 cebo began during week 4 of radiotherapy and
was continued for up to 12 cycles of maintenance chemoth
114 treated for at least 3 months and treatment
was continued for up to 12 months.
115 was interrupted, and Peg-interferon alfa-2a
was continued for up to 12 weeks (the primary end point)
116 60 mg/m(2) once every 4 weeks, and treatment
was continued for up to 12 weeks if no disease progressi
117 Treatment
was continued for up to 42 months until recovery was ach
118 The study drug
was continued for up to 60 days.
119 2 months after infection, and the treatment
was continued for up to a year postinfection.